Literature DB >> 33094871

Clinical practice guide for the treatment of perforating dermatosis.

Tamihiro Kawakami1, Masashi Akiyama2, Akemi Ishida-Yamamoto3, Hajime Nakano4, Chikage Mitoma5, Kozo Yoneda6, Yasushi Suga7.   

Abstract

Perforating dermatoses are a heterogeneous skin disease group defined by transepidermal elimination of various skin materials. Four classical forms of primary perforating dermatosis have been described, where the transepidermal elimination mechanism represents the hallmark of the disease: acquired reactive perforating collagenosis, elastosis perforans serpiginosa, Kyrle's disease and perforating folliculitis. Acquired reactive perforating collagenosis presents with transepidermal elimination of collagen fibers. Elastosis perforans serpiginosum presents with the elimination of elastic fibers. Kyrle's disease presents with transepidermal elimination of abnormal keratin. In perforating folliculitis, it is the content of the follicle. We established diagnostic criteria and severity classification. In addition, the Japanese guideline for treatment of perforating dermatoses was updated using the Medical Information Network Distribution Service (MINDS) methodology. The guideline is based on a systematic published work review completed from 1989 to 2019, and on a formal consensus and approval process. Most medical published work on the treatment is limited to individual case reports and small series of patients. The guideline covers treatment options considered relevant by the expert panel and approved in Japan at the time of the consensus conference.
© 2020 Japanese Dermatological Association.

Entities:  

Keywords:  Kyrle’s disease; acquired reactive perforating collagenosis; elastosis perforans serpiginosa; perforating dermatosis; perforating folliculitis

Mesh:

Year:  2020        PMID: 33094871     DOI: 10.1111/1346-8138.15647

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  3 in total

Review 1.  Colchicine in Managing Skin Conditions: A Systematic Review.

Authors:  Stefano Dastoli; Steven Paul Nisticò; Pietro Morrone; Cataldo Patruno; Antonio Leo; Rita Citraro; Luca Gallelli; Emilio Russo; Giovambattista De Sarro; Luigi Bennardo
Journal:  Pharmaceutics       Date:  2022-01-27       Impact factor: 6.321

2.  Reactive perforating collagenosis successfully treated with dupilumab.

Authors:  Javier Gil-Lianes; Constanza Riquelme-Mc Loughlin; Jose Manuel Mascaró
Journal:  Australas J Dermatol       Date:  2022-05-28       Impact factor: 2.481

3.  Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD.

Authors:  Yang Ying; Chen Shuang; Zhang Zhen-Ying
Journal:  Immun Inflamm Dis       Date:  2021-12-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.